Smart science to improve lives™

Croda announces Global Technical Centre in Hyderabad

21 June 2023: On June 21, 2023, Croda International Plc, the company that uses smart science to create high-performance ingredients and solutions that improve lives, opened its new Global Technical Centre at Genome Valley, Hyderabad, India. The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for Life Sciences, reinforcing the company’s Purpose to use Smart science to improve lives™. 

Croda officially opened the Global Technical Centre with a ribbon cutting celebration led by President of Life Sciences, Daniele Piergentili. The centre, based in ‘Genome valley’, will increase Croda’s capability to provide advanced and sustainable solutions to its pharmaceutical customers, and is a significant step towards establishing Croda’s presence in Telangana, a critical hub supporting India’s position as the ‘Pharmacy of the World’.

This latest expansion will focus on the development of new ingredients, generation of application data and training for small molecule and biologic applications, enabling the company to provide specialised solutions for the pharmaceutical industry. The facility will focus on housing collaborative work with customers to help them tackle their formulation challenges during development and troubleshoot faster.  As per Croda’s global safety standards, the new facility is meticulously designed to ensure the safety of those working within it.  Croda also recently marked a new milestone by breaking ground on a new greenfield manufacturing plant at Dahej, Gujarat.

Daniele Piergentili, President of Life Sciences, explains the significance of this strategic investment: “This new technical centre represents our commitment to supporting pharmaceutical innovators and manufacturers in the region. We are committed to supporting drug development in Asia and collaborating with customers here to develop cutting-edge drug delivery technologies alongside them”.

In addition to the company’s rich history of innovation for small molecule and consumer health products, Croda has been recognised for its development and support of ingredients for biologic applications. Last year, the company was awarded “Best Supplier for COVID-19 Vaccine Development” at the India Biologics & Vaccines Outstanding Industry Awards (BVOIA) 2022 for its work during the pandemic. 

More recently, Croda was awarded funding by both the UK and US Government to expand its manufacturing facilities to continue to enhance the development of high-purity lipid systems – essential delivery systems for next generation pharmaceutical drugs such as mRNA vaccines.


About Croda

Established in 1925, Croda is the name behind sustainable, high-performance ingredients and technologies in some of the world’s most successful brands: creating, making, and selling speciality chemicals that are relied on by industries and consumers everywhere.

Croda is a FTSE 100 company with over 5,800 passionate and innovative employees, working across manufacturing sites and offices around the world with a shared Purpose to use Smart science to improve lives™. As part of this Purpose, and with around two thirds of its organic raw materials already from bio-based sources, Croda has committed to be the most sustainable supplier of innovative ingredients, becoming Climate, Land and People Positive by 2030. 

Croda India Company Pvt. Ltd is 100% subsidiary of Croda Plc., (UK), currently with manufacturing operations at Navi Mumbai, Thane, Maharashtra. 


About Croda


Croda Pharma is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations. The company is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid delivery platforms. With a wide range of solutions for both human and animal health markets, the pharmaceutical portfolio is unsurpassed in its excellence. Croda Pharma’s products, along with its in-house formulation and regulatory expertise, allows the company to meet its customers’ most demanding formulation needs. The company is committed to enabling the next generation of drug delivery systems.